MedTrace Logo

An Open-Label Study of Apabetalone in Covid Infection

NCT04894266 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-11-18

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

Conditions

  • COVID-19 Infection

Interventions

DRUG

Apabetalone

Apabetalone 100mg BID

OTHER

Standard of care

Standard of Care

Sponsors & Collaborators

  • Resverlogix Corp

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-14
Primary Completion
2022-06-22
Completion
2022-06-22
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04894266 on ClinicalTrials.gov